Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing led by TCGX with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio, and participation from UniQuest and founding investor Medicxi.
London-based Vicebio said funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using its proprietary Molecular Clamp technology.
The Company has begun a Phase I clinical study of a bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV).
Biocomposites to showcase innovations in infection management at EBJIS 2024
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, on Tuesday announced its participation as a Platinum Sponsor of the 42nd Annual Meeting of the European Bone & Joint Infection Society (EBJIS).
An abstract by Biocomposites’ researchers shows how calcium sulfate beads loaded with antifungals are effective in inhibiting drug-resistant strains of Candida auris.
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
Heidelberg Pharma AG, a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), on Tuesday announced that new data from its Phase I/IIa clinical study with lead Amanitin-based ADC candidate, HDP-101, will be presented at the 21st International Myeloma Society (IMS) Annual Meeting.
HDP-101 is an Anti-BCMA antibody-Amanitin drug conjugate for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with a high unmet medical need. Phase I of the trial is a dose escalation study to determine the optimal and safe dose level of HDP-101 in patients in preparation to commence Phase II clinical studies.
Come to the How to Have a Successful IPO on Nasdaq session at Our Conference
Optimum’s prestigious annual investor conference is almost upon us, held this year on Thursday 10th October at The King’s Fund in London.
Last year, we received repeated feedback that: “The conference should be longer!” So, for our 16th year, we are adding a bonus session – How to Have a Successful IPO on Nasdaq – at the earlier time of 11am. This brand-new session will be the tell all on how to maximise your chances for success when preparing to list across the pond. Experts from Citi, Nasdaq, Gilmartin Group and Optimum will be there to answer your questions.
Check out the latest episode of Optimum TV as we count down towards our 16th Annual Healthcare Investor Conference
Watch Allan Marchington, MD and Head of Life Sciences at ICG, talk about how the life sciences market is “climbing back out” after a difficult couple of years. “In terms of the market overall, people are being a little bit more choosy about where they invest” than in the past, he said. But as the year moves towards its conclusion “I think the pace is going to step up,” he predicted.
To watch more episodes with top investors and life sciences leaders, head to Optimum TV here: https://www.optimumcomms.com/optimumtv/
